1. Introduction {#sec1}
===============

Hypertension is one of the most common causes of premature morbidity and death worldwide. More than 5.8% of the total deaths and more than 45% of deaths result from heart diseases are caused by hypertension \[[@bib1]\]. The slight increase in blood pressure if untreated raises the risk of cardiovascular diseases and organ damage \[[@bib2]\]. Hypertension can be strongly controlled by vasorelaxation that decreases peripheral resistance and blood flow \[[@bib3]\]. Vasorelaxation is achieved by activating endogenous or exogenous vasoactive compounds that act on the receptors, channels, or enzymes located on vascular endothelium or vascular smooth muscle \[[@bib4], [@bib5]\]. Therefore, finding new drugs that are capable of employing multiple vasorelaxant mechanisms is highly desired.

All over the world, medicinal plants have been used as part of society due to many factors, including affordability, accessibility, and less toxicity \[[@bib6]\]. *Vitex pubescens* Vahl. (Verbenaceae) locally called Halban in the Peninsular of Malaysia has been used traditionally to treat hypertension and gastrointestinal disorders \[[@bib7], [@bib8]\]. In Brunei folk medicine, young leaves of *V. pubescens* are eaten raw for treating hypertension and fever \[[@bib9]\]. Bhakuni et al. \[[@bib10]\] have reported hypotensive activity of *V. pubescens* from *in vitro* study of cardiovascular effects of ethanol (50 %) extract on dogs. Vitexin is an important flavonoid with a potent hypotensive effect \[[@bib11]\] and induces vasorelaxation in rat aorta \[[@bib12]\]. Thenmozhi et al. \[[@bib13]\] have reported the isolation of vitexin, an apigenin flavone glycoside, from hydroalcoholic leaves extract of *V. pubescens*.

Although the hypotensive activity of *V. pubescens* has been reported, there is no study on the antihypertensive and vasorelaxant activities of this plant so far. Therefore, this study investigated the antihypertensive activity of *V. pubescens* using conscious SHRs and the mechanism of its vasorelaxant activity using isolated SHR aortic rings.

2. Materials and methods {#sec2}
========================

2.1. Chemicals {#sec2.1}
--------------

Petroleum ether, chloroform, methanol, n-hexane, and acetone were purchased from Fischer Scientific (Selangor, Malaysia). Phenylephrine (PE), acetylcholine (ACh), Nω-nitro-L-arginine methyl ester (L-NAME), methylene blue (MB), atropine, indomethacin, glibenclamide, propranolol hydrochloride, and verapamil hydrochloride were purchased from Sigma-Aldrich Company (St Louis, Mo, USA). All chemical substances were of analytical quality.

2.2. Animals {#sec2.2}
------------

Male spontaneously hypertensive rats (SHRs, 250--320 g) were obtained from and housed in the Animal Research and Service Centre Universiti Sains Malaysia (ARASC-USM). The SHRs were kept at 27 °C with a 12-h light/12-h dark cycle with standard rat diet (Gold Coin) and water *ad libitum*. The study was conducted in accordance with the USM Guide for the Use and Care of Laboratory Animals and approved by the Animal Ethics Committee, Universiti Sains Malaysia. \[No. of Animal Ethics Approval: USM/IACUC/2017/ (110) (897)\].

2.3. Plant material and preparation of *V. pubescens* extracts {#sec2.3}
--------------------------------------------------------------

Fresh green leaf samples of *V. pubescens* were gathered from the main campus of Universiti Sains Malaysia, Penang, Malaysia. The plant was authenticated by Rahmad Zakaria, Ph.D. at the Herbarium, School of Biological Sciences, Universiti Sains Malaysia (Voucher specimen registration no. 11750). 2.5 kg of *V. pubescens* crushed dried leaves were subjected to successive extraction by maceration at 45 °C in a water bath sequentially, with petroleum ether, chloroform, methanol, and water. These extracts were filtered with Whatman filter paper (No. 1). The filtrates were concentrated by a rotary evaporator (Buchi, Switzerland), and oven-dried at 45 °C for the petroleum ether, chloroform, and methanol extracts, and freeze-dried for the water extract.

2.4. Fractionation of *V. pubescens* petroleum ether extract {#sec2.4}
------------------------------------------------------------

Based on the vasorelaxation study, *V. pubescens* petroleum ether extract had been established as the most potent extract and was selected for fractionation. 10 g of the extract was further fractionated by column chromatography using silica gel (230--400 mesh) as the stationary phase. The column was eluted with n-hexane containing increasing concentrations of acetone (10, 20, 30, 40, and 50% acetone) as the mobile phase \[[@bib14]\]. Fractions were collected and then analyzed on TLC plates using hexane/acetone (7:3).

2.5. Antihypertensive study {#sec2.5}
---------------------------

36 SHRs were divided randomly into 6 groups of six; positive control (verapamil, 15 mg/kg/day), negative control (10% Tween 80 in distilled water, 10 mL/kg/day), four groups of *V. pubescens*, namely petroleum ether (VPPE), chloroform (VPCE), methanol (VPME), and water (VPWE) (500 mg/kg/day). Each SHR received a daily oral feeding of respective treatment for two weeks. Systolic and diastolic blood pressures of the SHRs were measured at day 0 (before oral feeding), 3, 7, and 14 for the two weeks\' duration using a non-invasive tail-cuff method (CODA system, Kent Scientific, USA). The SHR was placed in an animal restrainer on a heating pad at 38 °C, and the tail was inserted in the occlusion and volume pressure recording (VPR) cuffs for the blood pressure reading. At the end of the day 14 blood pressure measurements, the SHRs were euthanized in ARASC-USM using carbon dioxide (CO~2~) gas inhalation (10%--30% per minute) in a chamber.

2.6. Isolated rat thoracic aortic rings preparation and vasorelaxation study of *V. pubescens* extracts {#sec2.6}
-------------------------------------------------------------------------------------------------------

Vasorelaxation assay was conducted as described by Bello et al. \[[@bib15]\]. The SHR was immobilized in the carbon dioxide (CO~2~) gas chamber and then exsanguinated. After opening the SHR\'s chest, the aorta was carefully taken out and placed in Krebs\'s Physiological Solution (KPS) (consisting of 118 mM NaCl, 4.7 mM KCl, 1.2 mM KH~2~PO~4~, 4.2 mM NaHCO~3~, 1.2 mM MgSO~4~, 10 mM glucose, and 2 mM CaCl~2~). The aorta was cleaned of the connective tissues and cut into 3--5 mm long aortic rings. These rings were hanged up horizontally in a tissue bath containing 10 mL KPS being continuously ventilated with carbogen gas (95% oxygen and 5% carbon dioxide) at 37 °C. Equilibration of the aortic rings was set at a basal tension of 1g for at least 30 min. During the experiment, the KPS in the aortic ring chamber was replaced every 15 min. For endothelium intact aortic ring preparation, the endothelium integrity was assessed by more than 90% relaxation of acetylcholine (1 μM) to phenylephrine (PE, 1 μM) precontracted rings. For the endothelium-denuded aortic ring preparation, endothelium denudation was attained by rubbing the intima with forceps and was later affirmed by the lack of relaxation to ACh (1 μM) of PE-precontracted rings \[[@bib16]\]. The vasorelaxant effects of the extracts/fractions that were added cumulatively (0.25, 0.5, 1, 2, and 4 mg/mL) to PE-precontracted aortic rings were determined. Percentage vasorelaxation was measured using the formula:$$\text{\%}\mspace{9mu} Relaxation = \left( \frac{Tc - Tt}{Tc} \right) \times 100$$Where Tc = gm contraction of aortic rings with PE (1 μM) and Tt = gm relaxation of aortic rings with extract/fraction. The tension was measured with a force-displacement transducer (GRASS FT03, U.K.). Signals were amplified by PowerLab 26T (AD Instrument, Australia) and read by LabChart-7 software \[[@bib17], [@bib18]\].

2.7. Effects of endothelium-dependent pathways in vasorelaxation mechanisms of the most active fraction of *V. pubescens* {#sec2.7}
-------------------------------------------------------------------------------------------------------------------------

Involvements of muscarinic cholinergic receptors, endothelium-derived nitric oxide, prostacyclin (PGI~2~) and cyclic guanosine monophosphate (cGMP) in the vasorelaxation mechanism were examined using endothelium-intact aortic rings incubated with atropine (1 μM; a competitive non-selective muscarinic receptor antagonist), L-NAME (10 μM; a nonspecific nitric oxide synthase inhibitor), indomethacin (10 μM; a non-selective cyclooxygenase inhibitor), and methylene blue (MB, 10 μM; a cGMP inhibitor), respectively. The aortic rings were precontracted with PE (1 μM), and then cumulative concentrations of the most active fraction of *V. pubescens* (0.25--4 mg/mL) were added. This was followed by the aortic rings incubation with a blocker, and the vasorelaxation procedures were repeated \[[@bib19]\].

2.8. Effects of the most active fraction of *V. pubescens* on β-adrenergic receptors and K^+^ channels using endothelium-denuded aortic rings {#sec2.8}
---------------------------------------------------------------------------------------------------------------------------------------------

K^+^ channels and β-adrenergic receptors involvements in the vasoactive mechanisms of *V. pubescens* most active fraction were examined using glibenclamide (1 μM; a selective ATP-sensitive K^+^ channel blocker) and propranolol (1 μM; a non-selective β-adrenergic receptor blocker), respectively. The aortic rings were precontracted with PE (1 μM), and then cumulative concentrations of the most active fraction (0.25--4 mg/mL) were added. This was followed by the aortic rings incubation with a blocker, and the vasorelaxation procedures were repeated \[[@bib20], [@bib21]\].

2.9. Effects of the most active fraction of *V. pubescens* on extracellular Ca^2+^-induced contraction using endothelium-denuded aortic rings {#sec2.9}
---------------------------------------------------------------------------------------------------------------------------------------------

Inhibitions of Ca^2+^ influx through voltage-dependent calcium channels (VDCC) by the most active fraction of *V. pubescens* were assessed as described by Oliveira et al. \[[@bib22]\]. Denuded aortic rings were equilibrated for 30 min in normal KPS. The solution was then replaced with Ca^2+^ free KPS containing EDTA (0.1 mM), and the aortic rings were continually being immersed for 30 min to get rid of Ca^2+^ from the tissue. The solution was further replaced with Ca^2+^ free, K^+^ rich KPS (92.6 mM NaCl, 16.09 mM KCl, 1.2 mM KH~2~PO~4~, 16.67 mM NaHCO~3~, 9.98 mM MgSO~4~, 11 mM glucose) for 30 min. The contraction effects of cumulative additions of Ca^2+^ (0.1--10mM) were compared before and after incubation with different concentrations of the *V. pubescens* most active fraction (0.5, 1, and 2 mg/mL) or verapamil (0.01 and 0.1 μM), respectively.

2.10. Effects of the most active fraction of *V. pubescens* on intracellular Ca^2+^-induced contractions using endothelium-denuded aortic rings {#sec2.10}
-----------------------------------------------------------------------------------------------------------------------------------------------

The inhibitions of PE-induced intracellular Ca^2+^ release by the most active fraction of *V. pubescens* were examined as described by Senejoux et al. \[[@bib23]\]. Denuded aortic rings were equilibrated in a Ca^2+^ free KPS containing EDTA (0.1 mM) before inducing the first transient contraction (*T*~*1*~) by PE (1 μM). The solution was then washed twice with the same solution. After that, the aortic rings were equilibrated and then incubated with the *V. pubescens* most active fraction (1 and 2 mg/mL, respectively) for 15 min before inducing the second transient contraction (*T*~*2*~) by PE (1 μM). The ratio of the second transient contraction to the first (*T*~*2*~*/T*~*1*~) was calculated.

2.11. GC--MS analysis of the most active fraction {#sec2.11}
-------------------------------------------------

As described by Zuo et al. \[[@bib24]\], gas chromatography-mass spectroscopy (GC-MS) analysis of the most active fraction (1 mg/mL) of *V. pubescens* was carried out using Agilent Technologies 6890N Network GC System coupled with an Agilent Technologies 5973 Mass Selective Detector and equipped with an Agilent 19091S-433 HP-5MS (5% Phenyl Methyl Siloxane) capillary column (30 m length × 250 μm diameter × 0.25 μm film thickness). The mass spectrum was acquired by an electron ionization at 69.9 eV and scanned from *m/z* 35 to 650 at a rate of 2 scans/sec. Helium gas was used as a carrier gas with a steady flow rate of 1.2 mL/min, and 2 μl of injection volume was used. The oven initial and maximum temperatures were 70 °C and 325 °C, respectively. The front inlet temperature was 280 °C with pressure at 10.97 psi in the splitless mode. The total running time was 32.50 min. The relative percentages of the determined compounds were calculated by the total ion chromatogram using ChemStation software. The mass-spectrum was interpreted by the database of the National Institute Standard and Technology (NIST02). The phytochemicals with their retention time (RT), chemical formula, chemical structure, and ethnopharmacological uses were listed.

2.12. Statistical analysis and data presentation {#sec2.12}
------------------------------------------------

All data were presented as mean ± SEM and n = 6. The effect of 14 days daily oral administration of extracts and control groups on SBP and DBP of SHRs were analyzed by one-way ANOVA, followed by Tukey\'s multiple comparison test. The other vasorelaxation experiments were analyzed by two-way ANOVA, followed by Tukey\'s multiple comparison test. All analyses were carried out using Graph Pad Prism statistical software (version 7). A significant difference was set at P \< 0.05, P \< 0.01, and P \< 0.001.

3. Results {#sec3}
==========

3.1. Extraction and fractionation of *V. pubescens* {#sec3.1}
---------------------------------------------------

The yields of the *V. pubescens* extracts petroleum ether (VPPE; 36.2 g), chloroform (VPCE; 27.8 g), methanol (VPME; 301.5 g), and water (VPWE; 183.0 g). The yields of the fractions of VPPE: F1-VPPE; 0.163 g, F2-VPPE; 1.620 g, F3-VPPE; 0.323 g, and F4-VPPE; 1.112 g.

3.2. Antihypertensive effects of *V. pubescens* extracts {#sec3.2}
--------------------------------------------------------

For the evaluation of antihypertensive effects of *V. pubescens* extracts, VPPE significantly reduced (P \< 0.001) SBP and DBP as early as day 3 during the 14 treatment days in a comparable manner as verapamil. VPME produced a significant reduction (P \< 0.01) only on day 14 ([Figure 1](#fig1){ref-type="fig"} and [Figure 2](#fig2){ref-type="fig"}).Figure 1The effects of 14 days daily oral administration of *V. pubescens* petroleum ether (VPPE), chloroform (VPCE), methanol (VPME), water (VPWE) extracts (500 mg/kg), negative control and verapamil (15 mg/kg) on SBP of SHRs. Means comparison between treatment days were analyzed by one-way ANOVA, followed by Tukey\'s multiple comparison test. Values are expressed as mean ± SEM (n = 6 SHRs). ∗∗*P* \< 0.01, ∗∗∗*P* \< 0.001 as compared to day 0.Figure 1Figure 2The effects of 14 days daily oral administration of *V. pubescens* petroleum ether (VPPE), chloroform (VPCE), methanol (VPME), water (VPWE) extracts (500 mg/kg), negative control and verapamil (15 mg/kg) on DBP of SHRs. Means comparison between treatment days were analyzed by one-way ANOVA, followed by Tukey\'s multiple comparison test. Values are expressed as mean ± SEM (n = 6 SHRs). ∗*P* \< 0.05, ∗∗*P* \< 0.01, ∗∗∗*P* \< 0.001 as compared to day 0.Figure 2

3.3. Vasorelaxation effects of *V. pubescens* extracts/fractions on the endothelium-intact aortic rings {#sec3.3}
-------------------------------------------------------------------------------------------------------

The cumulative additions of *V. pubescens* extracts to the tissue chamber elicited a concentration-dependent relaxation of PE-precontracted endothelium-intact aortic rings ([Figure 3](#fig3){ref-type="fig"}). VPPE significantly produced greater vasorelaxation (108.3 ± 4.3%, *P* \< 0.001) at 4 mg/mL concentration than VPCE (81.8 ± 4.2%), VPME (68.2 ± 4.7%), and VPWE (62.7 ± 3.7%), respectively. Whereas between the VPPE fractions, F2-VVPE significantly relaxed (*P* \< 0.001) the PE (1 μM)-precontracted intact aortic rings greater than F4-VPPE, F3-VPPE, and F1-VPPE, respectively ([Figure 4](#fig4){ref-type="fig"}). Therefore, F2-VPPE was selected for the vasorelaxation mechanism study using aortic rings.Figure 3The concentration-relaxation curves of *V. pubescens* petroleum ether (VPPE), chloroform (VPCE), methanol (VPME), and water (VPWE) extracts in PE pre-contracted intact aortic ring preparations. Means comparison between treatment groups were analyzed by two-way ANOVA, followed by Tukey\'s multiple comparison test. Values are expressed as mean ± SEM (n = 6 SHRs). ∗∗*P* \< 0.01, ∗∗∗*P* \< 0.001 as compared to VPCE, VPME and VPWE.Figure 3Figure 4The concentration-relaxation curves of sub-fractions (F1, F2, F3, and F4) of VPPE extract in phenylephrine pre-contracted intact aortic ring preparations. Means comparison between treatment groups were analyzed by two-way ANOVA, followed by Tukey\'s multiple comparison test. Values are expressed as mean ± SEM (n = 6 SHRs). ∗*P* \< 0.05 F2 vs F4. ∗∗*P* \< 0.01, ∗∗∗*P* \< 0.001 F2 vs F1 and F3.Figure 4

3.4. Effects of endothelium-dependent pathways in vasorelaxation mechanisms of F2-VPPE {#sec3.4}
--------------------------------------------------------------------------------------

F2-VPPE induced a concentration-dependent vasorelaxation in both endothelium-intact and endothelium-denuded aortic ring preparations pre-contracted with PE (1 μM) without any significant difference between the two aortic preparations ([Figure 5](#fig5){ref-type="fig"}). F2-VPPE also did not produce any significant decrease in concentration-dependent vasorelaxation in endothelium intact aortic rings following treatments with L-NAME, methylene blue ([Figure 6](#fig6){ref-type="fig"}), atropine, and indomethacin ([Figure 7](#fig7){ref-type="fig"}).Figure 5The concentration-relaxation curves of F2-VPPE on PE pre-contracted intact (E+) and denuded (E-) aortic ring preparations. Means comparison between treatment groups were analyzed by two-way ANOVA, followed by Tukey\'s multiple comparison test. Values are expressed as mean ± SEM (n = 6 rings).Figure 5Figure 6The concentration-relaxation curves of F2-VPPE on PE pre-contracted intact aortic rings in the absence and presence of L-NAME (10 μM) and methylene blue (10 μM). Means comparison between treatment groups were analyzed by two-way ANOVA, followed by Tukey\'s multiple comparison test. Values are expressed as mean ± SEM (n = 6 rings).Figure 6Figure 7The concentration-relaxation curves of F2-VPPE on phenylephrine pre-contracted intact aortic rings in the absence and presence of atropine (1 μM) and indomethacin (10 μM). Means comparison between treatment groups were analyzed by two-way ANOVA, followed by Tukey\'s multiple comparison test. Values are expressed as mean ± SEM (n = 6 rings).Figure 7

3.5. Effects of F2-VPPE on β-adrenergic receptors and K^+^ channels using endothelium-denuded aortic rings {#sec3.5}
----------------------------------------------------------------------------------------------------------

Glibenclamide significantly decreased (*P* \< 0.001) the vasorelaxation effects of F2-VPPE (from a concentration of 0.25--4 mg/mL) on PE pre-contracted endothelium-denuded aortic ring preparations but not propranolol ([Figure 8](#fig8){ref-type="fig"}).Figure 8The concentration-relaxation curves of F2-VPPE on phenylephrine pre-contracted intact aortic rings in the absence and presence of propranolol (1 μM) and glibenclamide (1 μM). Means comparison between treatment groups were analyzed by two-way ANOVA, followed by Tukey\'s multiple comparison test. Values are expressed as mean ± SEM (n = 6 rings). ∗∗*P* \< 0.01, ∗∗∗*P* \< 0.001 as compared to E-denuded.Figure 8

3.6. Effects of F2-VPPE on extracellular Ca^2+^-induced contraction using endothelium-denuded aortic rings {#sec3.6}
----------------------------------------------------------------------------------------------------------

Cumulative additions of CaCl~2~ (0.1--10 mM) to endothelium-denuded aortic rings in high K^+^ and Ca^2+^ free KPS induced concentration-dependent contractions. Both, F2-VPPE (0.5, 1 and 2 mg/mL) and verapamil (0.01 and 0.1 μM) significantly (*P* \< 0.001) attenuated the CaCl~2~-induced vasoconstriction of endothelium-denuded aortic ring preparation ([Figure 9](#fig9){ref-type="fig"} A and B) in a comparable manner.Figure 9Effects of A) F2-VPPE (0.5, 1, 2 mg/mL) and B) verapamil (0.01 and 0.1 μM) on calcium chloride-induced contraction of denuded aortic ring preparations. Means comparison between treatment groups were analyzed by two-way ANOVA, followed by Tukey\'s multiple comparison test. Values are expressed as mean ± SEM (n = 6 rings). ∗∗∗*P* \< 0.001 as compared to calcium chloride control.Figure 9

3.7. Effects of F2-VPPE on intracellular Ca^2+^-induced contractions using endothelium-denuded aortic rings {#sec3.7}
-----------------------------------------------------------------------------------------------------------

F2-VPPE (1 and 2 mg/mL) significantly attenuated (*P* \< 0.001) PE-induced vasoconstrictions of denuded aortic rings ([Figure 10](#fig10){ref-type="fig"}).Figure 10Effects of F2-VPPE (1 and 2 mg/ml) on PE-induced contraction of denuded aortic ring preparations. Values are expressed as mean ± SEM (n = 6 rings). ∗∗∗*P* \< 0.001 as compared to PE.Figure 10

3.8. GC-MS analysis {#sec3.8}
-------------------

The GC-MS analysis of F2-VPPE indicated the presence of a total of 76 volatile components. Seven compounds with 95% similarity and above based on NIST 02 library had been identified ([Table 1](#tbl1){ref-type="table"}). These compounds are sesquiterpenes alcohol, phytosterols, and terpenes that have been reported with main pharmacological activities. The quantitative analysis showed the majority presence of α-amyrin, spathulenol, β-amyrin, and phytol. However, only spathulenol has been reported to be a potent vasorelaxant of smooth muscles.Table 1Major compounds and their pharmacological activities obtained through GC-MS study of F2-VPPE.Table 1RT (min)Peak AreaCompound nameChemical formula/structurePharmacological actionsReferences9.045.49SpathulenolC~15~H~24~O\
![](fx1.gif)Vasorelaxation of smooth muscle, antiinflammatory, antimicrobial and antioxidant\[[@bib35], [@bib36]\]9.470.70α-cadinolC~15~H~26~O\
![](fx2.gif)Antifungal, anticancer and pesticide\[[@bib37], [@bib38]\]11.713.90PhytolC~20~H~40~O\
![](fx3.gif)Antibacterial, antiinflammatory, and antiallergic\[[@bib39], [@bib40]\]22.290.96StigmasterolC~29~H~48~O\
![](fx4.gif)Antiinflammatory, antihypercholesterolemia, antitumor, antioxidant and antibacterial\[[@bib41], [@bib42]\]23.592.98β-sitosterolC~29~H~50~O\
![](fx5.gif)Antiinflammatory antihypercholesterolemia, anticancer and antidiabetic\[[@bib43]\]24.495.15β-amyrinC~30~H~50~O\
![](fx6.gif)Gastroprotective and antiplatelet\[[@bib44], [@bib45]\]25.6813.7α-amyrinC~30~H~50~O\
![](fx7.gif)Gastroprotective and antiplatelet\[[@bib44], [@bib45]\]

4. Discussion {#sec4}
=============

The present study is the first Bioactivity-guided approach for antihypertensive activities of *V. pubescens* leaf using conscious SHRs and the mechanism of its vasorelaxant activity using isolated SHR aortic rings. Based on the antihypertensive evaluation, VPPE produced the most significant blood pressure-lowering activity in SHRs, which was comparable to verapamil, a calcium channel blocker. Vasorelaxation is an important mechanism in lowering blood pressure as it decreases systemic vascular resistance. As in the whole animal measurement, VPPE exhibited the most significant concentration-dependent relaxation on isolated PE-precontracted rat thoracic aorta rings. Both findings suggested that the antihypertensive effects of VPPE might be largely due to its vasorelaxation activities which lead to a reduction in the peripheral resistance, and consequently lower diastolic and systolic blood pressure. We also established that F2-VPPE was the most potent fraction for vasorelaxation effects and was selected for the vasoactive mechanism study.

The endothelium regulates vascular activities by modulating the action of the contractile agents existed on the vascular smooth muscle layer of blood vessels through the production of endothelium-derived relaxing factors (EDRFs), including nitric oxide (NO), prostacyclin and various hyperpolarizing factors derived from endothelium \[[@bib25], [@bib26]\]. Our results showed that F2-VPPE-induced vasorelaxation effects were not influenced by the presence or absence of an intact endothelium. Further support of endothelium independence in F2-VPPE-induced vasorelaxation was confirmed by examining the effect of the selective blockers/inhibitors of EDRFs. This assumption has been reported in many therapeutic plants such as *Ligusticum chuanxiong* \[[@bib27], [@bib28], [@bib29]\]. Studies with L-NAME, indomethacin, methylene blue, and atropine further supported the irrelevancy of the nitric oxide and prostacyclin pathways, cGMP, and muscarinic receptors roles in the vasorelaxation properties of F2-VPPE.

Having established the role of endothelium and EDRFs, we investigated the participation of vascular smooth muscles in the vasorelaxation of *V. pubescens*. Roles of β-adrenergic receptors, potassium channels, and calcium channels in the vascular smooth muscles on F2-VPPE induced relaxation in endothelium-denuded aortic ring preparations were studied. Glibenclamide significantly reduced the F2-VPPE-induced relaxation but not propranolol, implying that K~ATP~ channel activation is largely involved in the vasorelaxation mechanism of F2-VPPE and not are β-adrenoceptors. The opening of the K~ATP~ channel leads to hyperpolarization, causing inhibition of Ca^2+^ inflow through voltage-dependent Ca^2+^ channels and relaxation of vascular smooth muscle \[[@bib30]\]. Extracellular Ca^2+^ inflow induces vascular smooth muscle contraction by opening voltage-dependent Ca^2+^ channels (VDCC) \[[@bib31]\]. The present results showed that F2-VPPE and verapamil (Ca^2+^ channel blocker) almost completely abolished the contraction prompted by the cumulative addition of CaCl~2~. This may imply that F2-VPPE inhibited the extracellular Ca^2+^ inflow through VDCC in a similar way as verapamil \[[@bib32]\].

Phenylephrine increases extracellular Ca^2+^ inflow and induces vascular smooth muscle contraction by opening receptor-operated Ca^2+^ channels (ROCC). Furthermore, phenylephrine induces contraction in the absence of extracellular Ca^2+^ by the release of intracellular Ca^2+^ from the sarcoplasmic reticulum Ca^2+^ store via 1,4,5-triphosphate inositol receptors (IP3Rs) which bind to IP3 \[[@bib33]\]. Our results also showed that F2-VPPE inhibited PE-induced contraction that could be due to an inhibition of intracellular Ca^2+^ release from Ca^2+^ store and/or inhibition of extracellular Ca^2+^ inflow through ROCC. From these results, it is most likely that F2-VPPE-induced vasorelaxation involves K~ATP~ channels activation, inhibition of the extracellular Ca^2+^ inflow through VDCC, and inhibition of intracellular Ca^2+^ release from Ca^2+^ store and/or inhibition of extracellular Ca^2+^ inflow through ROCC in the vascular smooth muscles.

Based on the GC-MS analysis of F2-VPPE, spathulenol was one of the main compounds identified. It has been reported by Dib et al. \[[@bib34]\] that spathulenol is a predominant compound in therapeutic plants that possess vasorelaxant activity. Perez et al. \[[@bib35]\] stated that spathulenol, isolated from *Lepechinia caulescens,* induces relaxation of smooth muscles by inhibiting the contraction prompted by the cumulative addition of CaCl~2~ and thus inhibiting the Ca^2+^ inflow through VDCC.

5. Conclusion {#sec5}
=============

These findings showed that *V. pubescens* possesses antihypertensive effects. The most potent fraction, F2-VPPE, exerted its endothelium-independent vasorelaxation by inhibition of vascular smooth muscle contraction induced by extracellular Ca^+2^ influx through trans-membrane Ca^+2^ channels and/or Ca^+2^ release from intracellular stores, and by activation of K~ATP~ channels. The vasorelaxation effects of *V. pubescens* could be due to the compound, spathulenol.
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